Payment overview · 2025
General Payments
$176.49
9 reported records · 8 companies
Healthcare provider profile · identity verified
Dipeshkumar Shah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHBROOK, IL · NPI 1144236233
Verified facts
What the public records show
CMS Open Payments records show Dipeshkumar Shah, MD received $176.49 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.51 | 20.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.82 | 15.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.92 | 13.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.44 | 12.7% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $19.08 | 10.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.55 | 10.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.79 | 9.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $14.38 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.49 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 425 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
425 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 901 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 85 |
| Eliquis | Apixaban | 425 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 86 |
| Omeprazole | Omeprazole | 367 | 80 |
| Lisinopril | Lisinopril | 331 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 33 |
| Gabapentin | Gabapentin | 223 | 39 |
| Mirtazapine | Mirtazapine | 223 | 18 |
| Losartan Potassium | Losartan Potassium | 215 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 44 |
| Allopurinol | Allopurinol | 194 | 45 |
| Potassium Chloride | Potassium Chloride | 179 | 27 |
| Tramadol Hcl | Tramadol Hcl | 147 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 42 |
| Metformin Hcl | Metformin Hcl | 137 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 20 |
| Ezetimibe | Ezetimibe | 120 | 35 |
| Sertraline Hcl | Sertraline Hcl | 120 | 27 |
| Carvedilol | Carvedilol | 110 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 32 |
| Alprazolam | Alprazolam | 106 | 21 |
| Donepezil Hcl | Donepezil Hcl | 105 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 12 |
| Trazodone Hcl | Trazodone Hcl | 103 | 29 |
| Memantine Hcl | Memantine Hcl | 102 | 13 |
| Warfarin Sodium | Warfarin Sodium | 102 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 99 | 13 |
| Alendronate Sodium | Alendronate Sodium | 93 | 24 |
| Simvastatin | Simvastatin | 92 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 14 |
| Finasteride | Finasteride | 82 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 22 |
| Bumetanide | Bumetanide | 79 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | suppressed |
| Valsartan | Valsartan | 75 | 16 |
| Azithromycin | Azithromycin | 71 | 57 |
| Montelukast Sodium | Montelukast Sodium | 70 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 37 |
| Rybelsus | Semaglutide | 64 | 17 |
| Cephalexin | Cephalexin | 61 | 12 |
| Furosemide | Furosemide | 61 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 20 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Olanzapine | Olanzapine | 48 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 48 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Meloxicam | Meloxicam | 45 | 20 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 14 |
| Baclofen | Baclofen | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 21 |
| Atenolol | Atenolol | 42 | 12 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ozempic | Semaglutide | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 20 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Trimethoprim | Trimethoprim | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Risperidone | Risperidone | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 20 | 14 |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.49 · 9 records | Exact Sciences Corporation | ELIQUIS, FREESTYLE LIBRE 3, Fibroscan, Ozempic, REXULTI, Rybelsus, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error